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ABSTRACT.
Retinopathy of prematurity (ROP) is a disease that can cause blindness in very
low birthweight infants. The incidence of ROP is closely correlated with the weight
and the gestational age at birth. Despite current therapies, ROP continues to be a
highly debilitating disease. Our advancing knowledge of the pathogenesis of ROP
has encouraged investigations into new antivasculogenic therapies. The purpose of
this article is to review the findings on the pathophysiological mechanisms that con-
tribute to the transition between the first and second phases of ROP and to investi-
gate new potential therapies. Oxygen has been well characterized for the key role
that it plays in retinal neoangiogenesis. Low or high levels of pO2 regulate the nor-
mal or abnormal production of hypoxia-inducible factor 1 and vascular endothelial
growth factors (VEGF), which are the predominant regulators of retinal angiogen-
esis. Although low oxygen saturation appears to reduce the risk of severe ROP
when carefully controlled within the first few weeks of life, the optimal level of sat-
uration still remains uncertain. IGF-1 and Epo are fundamentally required during
both phases of ROP, as alterations in their protein levels can modulate disease
progression. Therefore, rhIGF-1 and rhEpo were tested for their abilities to pre-
vent the loss of vasculature during the first phase of ROP, whereas anti-VEGF
drugs were tested during the second phase. At present, previous hypotheses con-
cerning ROP should be amended with new pathogenetic theories. Studies on the
role of genetic components, nitric oxide, adenosine, apelin and b-adrenergic recep-
tor have revealed new possibilities for the treatment of ROP. The genetic hypothe-
sis that single-nucleotide polymorphisms within the b-ARs play an active role in
the pathogenesis of ROP suggests the concept of disease prevention using b-block-
ers. In conclusion, all factors that can mediate the progression from the avascular
to the proliferative phase might have significant implications for the further under-
standing and treatment of ROP.
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Introduction
Over the past two decades, the survival
of premature infants has markedly
increased in industrialized countries
(Vermont Oxford Network Database,
https://nightingale.vtoxford.org),
whereas the neonatal mortality rate
worldwide – approximately 4 million
deaths each year – has remained virtu-
ally unchanged (Lawn et al. 2005, 2009;
Black et al. 2010; Carlo et al. 2010;
Ma˚lqvist 2011). Ninety-nine per cent of
these neonatal deaths affect underde-
veloped and developing countries
(Lawn et al. 2005).
Unfortunately, survival is affected
by premature death (1%) and several
forms of neurological impairment,
such as cerebral palsy (8%), cognitive
delay (10%), deafness (3%) and blind-
ness (1%) (Vermont Oxford Network
Database, https://nightingale.vtoxford.
org; Fanaroff et al. 2007; Wilson-
Costello et al. 2007; Wood et al.
2000). In extremely low birthweight
(ELBW) neonates, morbidity is ele-
vated, and retinopathy of prematurity
(ROP) can develop in the survivors.
Severe bronchopulmonary dysplasia
(BPD), brain injury and ROP,
together or separately, represent
strong prognostic indicators in ELBW
infants (Koo et al. 2010).
In 2010, the Vermont Oxford Net-
work Database (VON) estimated that
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the incidence of any form of ROP in all
very low birthweight (VLBW) infants
was 33.2% (Vermont Oxford Network
Database, https://nightingale.vtox-
ford.org). The incidence of this disease
is closely correlated with the weight
and the gestational age at birth; ROP
is more severe and more frequent in
extremely premature infants and those
with very low birthweights. Indeed, the
incidence of any ROP increases to
84.7% and 85%, and the incidence of
severe ROP (stage >2) is 40.7% and
39.2%, in infants weighing <501 g
and in those with a gestational age
<24 w, respectively (Koo et al. 2010).
A recent Norwegian study using the
Braille system in people with visual
loss revealed that ROP continues to
be one of the leading causes of blind-
ness in children (Augestad et al.
2012), although several studies have
demonstrated the importance and
contribution of unpreventable or un-
treatable disorders (including cerebral
visual impairment, hereditary retinal
dystrophies and optic nerve atrophy
and hypoplasia) (Rahi & Cable 2003;
Boonstra et al. 2012).
Although the incidence rates and
age distribution of the risk population
for ROP are well established, to date,
the pathogenetic mechanisms underly-
ing ROP remain poorly understood.
This review summarizes the previous
and new pathogenic hypotheses on the
development of ROP, involving fac-
tors such as hypoxia-inducible factor 1
(HIF-1), vascular endothelial growth
factors (VEGFs), insulin-like growth
factor-1 (IGF-1), erythropoietin (Epo),
placental growth factor (PlGF), nitric
oxide (NO), adenosine, apelin, as well
as the most recent and innovative the-
ory on the role of the sympathetic ner-
vous system and polymorphisms of the
beta-adrenoreceptors (b-ARs). The
theoretical mechanisms responsible for
retinal neovasculogenesis are illus-
trated in Fig. 1. In addition, we
describe the new potentially preventive
and therapeutic modalities that arise
from these hypotheses.
Normal Retinal Vascular
Development
In the human retina, five cell types
form the ‘vascular complex’: vascular
endothelial cells, astrocytes, microglia,
pericytes and a complex of three cell
types (neuronal substance P (SP)-
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Fig. 1. The mechanisms induced by hypoxia to produce proangiogenic factors. 5¢N: 5¢ nucleotidase; A1-R: Adenosine A1 receptor; A2-R: adeno-
sine A2 receptor; AC: adenylate cyclise; Akt: non-specific serine ⁄ threonine protein kinase; AMP: adenosine monophosphate; APJ: apelin receptor;
ARNT: aryl hydrocarbon receptor nuclear translocator; ATP: adenosine-5¢-triphosphate; cAMP: cyclic adenosine monophosphate; cGMP: cyclic
guanosine monophosphate; EGLN: prolyl hydroxylase; eNOS: endothelial nitric oxide synthase; Epo: erythropoietin; EpoR: erythropoietin recep-
tor; FLT-1: fms-related tyrosine kinase 1 receptor; Gia: a subunit of the inhibitory G protein; Gq: G protein q; GRK2: G protein–coupled recep-
tor kinase 2; Gsa: a subunit of the stimulatory G protein; Gbc: b and c subunit of the G protein; HIF-1: hypoxia-inducible factor 1; HRE:
hypoxia response element; IGF-1: insulin-like growth factor-1; IGF-1R: insulin-like growth factor-1 receptor; iNOS: inducible nitric oxide syn-
thase; KDR: kinase insert domain–containing receptor; MAPK: mitogen-activated protein kinase; NMDA-R: N-methyl-D-aspartate receptor;
nNOS: neuronal nitric oxide synthase; NO: nitric oxide; O2: oxygen; PDE: phosphodiesterase; PDE3: phosphodiesterase 3; PI3K: phosphatidyl-
inositol 3-kinases; PKA: protein kinase A; PlGF: placental growth factor; VEGF: vascular endothelial growth factor; VHL: von Hippel–Lindau
protein; b2-AR: b2-adrenergic receptor; b3-AR: b3-adrenergic receptor; bC-R: common b receptor.
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containing, nitric oxide synthase
(NOS)-containing and dopaminergic
amacrine-like cells) (Provis 2001).
Endothelial and microglial cells
proliferate and invade into the retina
during fetal development. The glial
fibrillary acidic protein (GFAP)-
immunoreactive astrocytes are
involved in the process of vasculogene-
sis. In fact, they precede the front of
vascularization by a few hundred
microns, and their proliferation
appears to be associated with the
release of proliferative factors by the
endothelial cells (Provis 2001). These
astrocytes are highly sensitive to
hypoxia, and under conditions of low
oxygen saturation, they release VEGF,
which in turn stimulates the migration,
differentiation and proliferation of
endothelial cells (Provis 2001).
Vascular development comprises
two phases (Hughes et al. 2000): vas-
culogenesis and angiogenesis. The for-
mer phase is characterized by the
denovo formation of blood vessels
from endothelial precursor cells within
the central retina, whereas the latter
phase is characterized by the develop-
ment of new blood vessels that bud
from existing blood vessels. During
the vasculogenic period, four vascular
arcades are formed. The tissue
hypoxia that stimulates the produc-
tion of VEGF does not appear to be
necessary for this stage of retinal vas-
cular development.
Angiogenesis is responsible for
increasing the vascular density and
peripheral vascularization of the
superficial retina and for forming the
outer plexus and radial peripapillary
capillaries. The mechanisms underly-
ing the generation of the retinal vascu-
lature have been found to be similar
to those of the central nervous system
(Hughes et al. 2000). Similar to what
is observed in brain tissues, angiogenic
sprouting represents the predominant
mechanism of retinal vascularization,
although there are additional modes
of vascular growth, such as intussus-
ception (Flower et al. 1985; Gariano
2003; Gariano & Gardner 2005). The
angiogenic system is controlled by a
balance between the activation and
the inhibition of regulatory factors
(Carmeliet & Jain 2000; Talks & Har-
ris 2000; Chader 2001). During fetal
development, relative hypoxia pro-
motes retinal development (Chen &
Smith 2007). Indeed, hypoxia stimu-
lates the production of HIF-1, a
nuclear transcription factor that regu-
lates VEGF. HIF-1 is rapidly
degraded during normoxia, but in
moderately hypoxic conditions, such
as those present during fetal life, its
half-life is prolonged, promoting its
nuclear accumulation. After HIF-1
stimulation, VEGF is secreted pre-
dominantly by retinal astrocytes and
Muller cells, thereby inducing angio-
genesis.
Pathological Retinal
Development
The relationship between oxygen sup-
ply and ROP has been well known
since the 1950s (Campbell 1951; Patz
et al. 1952; Ashton et al. 1953; Kinsey
1956; Patz & Eastham 1957). Further-
more, several retrospective and pro-
spective studies on the restrictive use
of oxygen have revealed a decrease in
the incidence and severity of ROP
(Tin et al. 2001; Chow et al. 2003;
Anderson et al. 2004; VanderVeen
et al. 2006; Wright et al. 2006; Sears
et al. 2009; Tokuhiro et al. 2009;
SUPPORT Study Group of the
Eunice Kennedy Shriver NICHD
Neonatal Research Network 2010;
Wiwatwongwana et al. 2010),
although some studies have failed to
establish such a correlation (Deulofeut
et al. 2006; Wallace et al. 2007; Tlucek
et al. 2010). Low oxygen saturation
might appear to reduce the risk of
severe ROP when carefully controlled
within the first weeks of life, but the
optimal level of saturation remains
uncertain. A meta-analysis conducted
by Chen et al. (2010) revealed that the
use of low oxygen saturation (70–
96%) during the first 8 weeks resulted
in a 52% reduction in the ROP risk
compared to the use of high concen-
trations (94–99%). The beneficial
effects of low oxygen concentrations
can be explained by the pathogenesis
of ROP (Smith 2004). Moreover, hy-
peroxia also induces the formation of
reactive oxygen species (ROS), such as
peroxynitrite. Hyperoxia-induced per-
oxynitrite might trigger apoptosis of
retinal endothelial cells (Gu et al.
2003).
Historically, ROP is defined as a
two-stage disease, although the devel-
opment of neovascularization might
be gradual and not well defined. The
first stage begins with the interruption
of normal retinal development at the
time of preterm birth, accompanied
by a sudden reduction in insulin-like
growth factor-1 (IGF-1) and VEGF
(Smith 2004). Smith observed the
importance of IGF-1 during the devel-
opment of the two phases. VEGF and
IGF-1 contribute to the development
of the disease. Indeed, IGF-1 was
found to be significantly lower in
infants who developed ROP than
those who did not, suggesting that the
administration of IGF-1 within the
first stage of ROP might inhibit
the progression to the second stage
(Smith 2004).
The second phase of ROP begins at
32–34 weeks postmenstrual age (PMA)
and is characterized by increased
hypoxia of the avascularized retina.
The vascular obliteration that occurs
secondary to hypoxic stimulation both
up-regulates VEGF and erythropoietin
and stimulates neovascularization
(Chan-Ling et al. 1995). Furthermore,
IGF-1 regulates the neovascularization
within this stage by acting as an ampli-
fying factor for VEGF (Smith 2004).
The progression from the avascular
to the proliferative phase is attributed
to the gap between the insufficient
capillary circulation and the increased
metabolic demands of the developing
retina. Neovascularization can regress
if adequate oxygenation is administered.
The neovascularization and secondary
cicatricial fibrosis are responsible for
retinal detachment and the associated
blindness.
However, this interpretation of the
progression from the first to the sec-
ond phase of ROP is quite imprecise;
all possible explanations of this transi-
tion could have significant implica-
tions for understanding and treating
ROP.
The Role of Hypoxia-
Inducible Factor 1a
(HIF-1a)
HIF-1 is a heterodimer consisting of
a- and b-subunits that, in humans, are
encoded by the Hif-1a gene. Whereas
the a-subunit is regulated by hypoxia,
the b-subunit, known as the aryl
hydrocarbon receptor nuclear translo-
cator (ARNT), is constitutively
expressed (Wood et al. 1996). HIF-1
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mediates the transcription of VEGF.
During normoxic conditions, HIF-1 is
hydroxylated by prolyl hydroxylases
(EGLNs). This post-translational mod-
ification facilitates its binding to the
von Hippel–Lindau protein (VHL),
which results in the ubiquitination and
rapid degradation of HIF-1. During
hypoxia, hydroxylation becomes less
efficient, resulting in HIF-1 accumula-
tion and binding to a hypoxia response
element (HRE) within the VEGF pro-
moter. HIF-1a protein degradation is
extremely fast, making HIF-1a one of
the most well-known short-lived pro-
teins. At low oxygen concentrations,
the EGLNs become less effective, and
HIF-1a is no longer hydroxylated. This
impairs the ability of VHL to bind to
HIF-1, thereby inhibiting the process
of ubiquitination and degradation.
HIF-1a accumulates in the nucleus,
ultimately increasing VEGF expres-
sion (Fig. 1). HIF-1a expression is
induced during normal retinal devel-
opment, is down-regulated by hyper-
oxia and is up-regulated upon a
return to normoxic conditions – a
pattern that is temporally and spa-
tially correlated with VEGF expres-
sion. During fetal development, the
low oxygen concentrations inhibit the
activity of EGLNs, concomitantly
increasing local HIF-1a and VEGF
levels, which in turn improve vascu-
larization (Ozaki et al. 1999). Prema-
ture exposure to relative hyperoxia at
birth from 30–35 mmHg (in the
uterus) to 50–80 mmHg (in the extra-
uterine environment), which is further
increased in many cases by supple-
mental oxygen therapy, suppresses
HIF-1a levels, thus reducing VEGF
expression and inducing the oblitera-
tion of retinal capillaries.
The reduction in HIF-1 is essential
for the initiation and progression of
the first phase of ROP, whereas its
increase is essential for the second
phase. The decrease of HIF-1 activity
and ⁄or expression by mutations, poly-
morphisms or drugs reduces the oxy-
gen-induced neovascularization. Kim
et al. (2008) showed that treatment
with deguelin blocked the neovascu-
larization induced by oxygen by
reducing HIF-1 expression. Similarly,
Brafman et al. (2004) demonstrated
that oxygen-induced neovasculariza-
tion was reduced in RTP801 knockout
mice. Therefore, the drug-induced
down-regulation of HIF-1 might rep-
resent a new therapeutic target for
ROP (Xia et al. 2012).
In conclusion, both the negative
and positive modulations of HIF-1
play key roles in ROP development
(Table 1).
The Roles of Vascular
Endothelial Growth Fac-
tors (VEGFs)
Vascular growth factors are a family
of proteins composed of placenta
growth factor (PlGF), VEGF-A,
VEGF-B, VEGF-C, VEGF-D and the
viral VEGF homologue VEGF-E (Ol-
ofsson et al. 1998; Eriksson & Alitalo
1999; Ferrara 1999a; Persico et al.
1999). VEGF is known to play a key
role in angiogenesis (Ferrara & Davis-
Smyth 1997; Ferrara 1999b).
Various combinations of the eight
exons that constitute the VEGF gene
(Vegf) allow for the generation of
three predominant isoforms of human
VEGF (VEGF121, VEGF165 and
VEGF189). Each isoform binds to
two receptors, the fms-related tyro-
sine kinase 1 (FLT-1, also known as
VEGFR-l) and the kinase insert
domain–containing receptors (KDR,
also known as FLK-1 or VEGFR-2).
Heparin sulphate proteoglycans
(HSPGs), neuropilin 1 (NRP-l) and
NRP-2 are specific receptors for
VEGF165.
FLT-1 and KDR are present in all
embryonic tissues, although their
expression levels vary in relation to
gestational age (Peters et al. 1993).
Hypoxia regulates the expression of
the Flt-1 gene by inducing the binding
of HIF-1a to its promoter (Gerber
et al. 1997; Bellik et al. 2005).
Whereas the up-regulation of Flt-1 by
hypoxia promotes remodelling and
vascular tone (Bellik et al. 2005), in
contrast, the Kdr gene does not
appear to be regulated by HIF-1a
(Gerber et al. 1997). Kdr and Flt-1
undergo changes in expression in vas-
cular endothelial cells during develop-
ment: they are both highly expressed
during early gestation and are signifi-
cantly reduced by the end of gestation
(Shalaby et al. 1995).
Kdr is essential for vasculogenesis
and haematopoiesis; the loss of its
function during embryogenesis leads to
premature fetal death (Shalaby et al.
1995). In endothelial cells, the interac-
tion between VEGF and KDR results
in a phosphorylation process that is
more efficient than that induced by the
interaction between VEGF and FLT-1.
Therefore, KDR is the main receptor
that induces the proliferation, migra-
tion, differentiation and maturation of
endothelial cells, as well as vascular
permeability (Terman et al. 1992;
Quinn et al. 1993; Waltenberger et al.
1994; Bernatchez et al. 1999).
Models of retinal vasculogenesis
suggest that the maturation of photo-
receptors and neurons leads to the
development of a ‘physiological
hypoxia’ in the retina, which in turn
induces the expression of VEGF by
astrocytes and the proliferation of the
vascular endothelium (Chan-Ling
et al. 1995). Under the hypoxic condi-
tions during development, the astro-
cytes are a source of VEGF, which
stimulates retinal growth towards the
periphery (Provis 2001). This angio-
genesis consequently leads to a reduc-
tion of the negative-feedback effects
of hypoxia and VEGF. Similarly, the
expression of VEGF by Muller cells is
thought to regulate the development
of the deep vascular plexus (Stone &
Maslim 1997).
Vascular endothelial growth factors
plays a key role in ROP development
Table 1. Action of different factors on the
development of retinopathy of prematurity
(ROP).
Factor
Role in ROP
development
Phase of ROP
development
HIF-1 (fl) + 1
HIF-1 (›) + 2
VEGF (fl) + 1
VEGF (›) + 2
IGF-1 (fl) + 1
IGF-1 (›) + 2
NO (fl) + 1
NO (›) + 2
PlGF (›) + 1
Epo (fl) + 1
Epo (›) ? 2
Adenosine (fl) + 1
Adenosine (›) + 2
Apelin ? ?
b2-AR (›) + 2
b3-AR (›) ? 2
fl = decrease; › = increase; + = stimula-
tion; ? = not known; Epo = erythropoietin;
HIF-1 = hypoxia-inducible factor 1; IGF-
1 = insulin-like growth factor-1; NO = ni-
tric oxide; PlGF = placental growth factor;
VEGF = vascular endothelial growth factor;
b2-AR = b2-adrenergic receptor; b3-AR =
b3-adrenergic receptor.
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(Fig. 1). Indeed, VEGF expression is
down-regulated by hyperoxia during
the first phase of ROP, resulting in
the stunting and obliteration of the
vasculature, whereas it is up-regulated
by hypoxia in the second phase (Table
1). Pierce et al. (1996) showed that
supplemental oxygen significantly
reduces the level of VEGF mRNA,
whereas in contrast, vessel obliteration
is reduced by pretreatment with exog-
enous VEGF. Similarly, treatment
with hyperoxia reduces the VEGF in
the ischaemic retina during the second
phase of ROP. The retinal neovascu-
larization observed during the second
phase of ROP is reduced by the appli-
cation of VEGF inhibitors. The use of
intravitreal antisense oligodeoxynucle-
otides was demonstrated to reduce
neovascularization by approximately
31% (Robinson et al. 1996). Jiang
et al. (2009) observed that VEGF-
and HIF-1a-targeted small interfering
RNAs (siRNAs) were also able to
inhibit their effects on neovasculariza-
tion. The use of intravitreal bev-
acizumab, a humanized monoclonal
antibody that inhibits VEGF and that
is commonly used for age-related mac-
ular degeneration (AMD), reduces the
development of severe ROP and
simultaneously allows blood vessels to
grow towards the periphery (Mintz-
Hittner & Kuffel 2008; Dorta &
Kychenthal 2010; Mintz-Hittner et al.
2011; Wu et al. 2011; Spandau et al.
2012). More recently, the ranibizumab
was reported to be a preferred thera-
peutic agent due to its relatively
shorter half-life (Hoerster et al. 2012).
Indeed, whereas bevacizumab can
decrease serum levels of VEGF for
several weeks (Matsuyama et al. 2010;
Lee et al. 2011; Sato et al. 2012), rani-
bizumab reduces it only for a few
weeks, with a detectable increase by
the fourth week after intravitreal
treatment (Hoerster et al. 2012).
The Role of Insulin-Like
Growth Factor-1 (IGF-1)
IGF-1 is a maternally derived factor
that is provided via the placenta and
amniotic fluid (Langford et al. 1998).
During the fetal development, IGF-1
is a potent growth factor that also
acts as a mediator of several growth
hormone signalling pathways.
Hellstrom et al. (2001) demon-
strated that IGF-1 plays a key role
in the normal development of the ret-
ina and in the pathogenesis of ROP.
The deficiency of IGF-1 during the
early stages of postnatal life induces
abnormal retinal vascularization and
the development of ROP. IGF-1 null
mice exhibit significantly delayed reti-
nal growth, despite normal levels of
VEGF (Hellstrom et al. 2001). How-
ever, patients with a genetic defect in
IGF-1 production exhibit reduced ret-
inal vascularization (Hellstrom et al.
2002) that is not restored upon the
administration of VEGF alone. IGF-
1, which is repressed at birth, rapidly
increases in premature infants who
do not develop ROP. Thus, it has
been assumed that if IGF-1 levels
remain low then the vasculogenesis
will stop; the resulting avascular ret-
ina becomes hypoxic, and VEGF
accumulates in the vitreous. High
VEGF levels and normal IGF-1 lev-
els stimulate the neovasculogenesis
that is characteristic of ROP (Hell-
strom et al. 2001).
The normal VEGF and IGF-1 con-
centrations activate Akt signalling,
thus promoting the survival of endo-
thelial cells. Hellstrom et al. showed
that VEGF and IGF-1 can activate
Akt and that its activation is fivefold
higher if both cytokines are present
compared to either alone. However, if
IGF-1 is low, as observed during the
first phase of ROP, then VEGF can-
not activate Akt. This leads to an
increase in apoptosis despite normal
levels of VEGF (Hellstrom et al.
2001). In contrast, high IGF-1 levels,
as observed during the second phase
of ROP, block endothelial cell apop-
tosis and promote neoangiogenesis,
presumably by activating Akt signal-
ling (Table 1).
IGF-1 also regulates neovascular-
ization through the p44 ⁄ 42 MAPK
pathway, which allows for an increase
in VEGF activity and the resultant
stimulation of retinal endothelial cell
growth (Smith et al. 1999). Moreover,
Fukuda et al. (2002) showed that
IGF-1 stimulates HIF-1 expression
through the PI3K ⁄Akt and MAPK
pathways (Fig. 1).
The phases of ROP and the roles
that VEGF and IGF-1 play at differ-
ent stages are suggestive of the time
and approaches for intervention. For
instance, the inhibition of VEGF and
IGF-1 might prevent normal vascular
growth during the first phase,
whereas it might support the regres-
sion of the disease during the second
phase (Smith 2004). Similarly, recom-
binant human IGF-1 (rhIGF-1)
might reduce neovascularization when
administered during the first phase of
ROP, whereas it would increase neo-
vascularization if administered during
the second phase (Smith 2004; Van-
haesebrouck et al. 2009).
The Role of Placental
Growth Factor (PlGF)
Vascular endothelial growth factors
and placental growth factor (PlGF)
are members of a large family of pep-
tides that share many biochemical and
molecular characteristics (Olofsson
et al. 1996; Nicosia 1998). In contrast
to VEGF, PlGF has not been thor-
oughly studied in the context of
angiogenesis. One study, by Carmeliet
& Jain (2000), showed that PlGF
affects the angiogenic response by
binding to FLT-1.
Placental growth factor is a homod-
imeric glycoprotein that plays crucial
roles in promoting monocyte chemo-
taxis, collateral vessel development,
adult pathophysiological neovascular-
ization and endothelial cell prolifera-
tion and migration (Rakic et al. 2003).
It also acts as an important cofactor
during retinal neovascularization by
increasing the activity and expression
of VEGF (Luttun et al. 2002; Nagy
et al. 2003). VEGF and PlGF create a
heterodimer that binds to and acti-
vates FLT-1, leading to angiogenesis
(Michels et al. 2006; Cao 2009).
The action of PlGF is still unclear.
Some studies argue that it dimerizes
with VEGF to limit the binding of
VEGF to KDR (Cao et al. 1996;
Cunningham et al. 1999), thereby
reducing the migration and prolifera-
tion induced by VEGF. However, a
study by Carmeliet and Park showed
that the binding of PlGF to FLT-1
increases the amount of circulating
VEGF available to activate KDR
(Park et al. 1994; Carmeliet et al.
2001). Adini et al. (2002) showed that
VEGF-deficient mice die during the
first 2 weeks of life, whereas PlGF-
deficient mice develop normally. These
data indicate that PlGF is not essen-
tial for normal development. More-
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over, Michels et al. (2006) revealed
that PlGF deficiency inhibits the path-
ological angiogenesis and vascular
leakage observed in ischaemia, cancer
and wound healing. PlGF induces
tumour angiogenesis by recruiting cir-
culating haematopoietic progenitor
cells and macrophages to the site of
the growing tumours (Schlingemann
2004). PlGF can be found together
with VEGF in retinal endothelial cells
and pericytes (Yonekura et al. 1999).
Simpson et al. (1999) observed that all
members of the VEGF family are up-
regulated during hypoxic conditions,
except for PlGF, which decreases
during hypoxia and increases during
hyperoxia (Fig. 1; Table 1). PlGF is
up-regulated during angiogenesis
(Khaliq et al. 1998; Nomura et al.
1998; Yamashita et al. 1999; Bottom-
ley et al. 2000; Carmeliet et al. 2001),
although its temporal expression
depends on the affected tissue and the
nature of the pathology. Specifically,
the up-regulation of PlGF in the ret-
ina is delayed during ROP, suggesting
that it can contribute to the neoangio-
genesis induced by VEGF (Khaliq
et al. 1998; Carmeliet et al. 2001).
Adini et al. (2002) demonstrated an
antiapoptotic action of PlGF. More-
over, a study conducted in an oxygen-
induced retinopathy (OIR) model by
Shih et al. (2003) confirmed the antia-
poptotic action of PlGF during hyper-
oxia. Zhao et al. (2003) showed that
VEGF and hyperglycaemia can induce
PlGF expression through the MAPK
signalling pathway and, partially,
through protein kinase C (PKC). Ak-
rami et al. (2011) showed that PlGF
acts as a proangiogenic factor for reti-
nal endothelial cells. The authors
speculated that the suppression of the
PlGF gene might reduce pathological
angiogenesis, suggesting a new thera-
peutic strategy for ocular neovascular
diseases. The blockade of PlGF func-
tion through the use of antagonists to
FLT-1 (Bae et al. 2005) or by mono-
clonal antibodies against FLT-1
(Luttun et al. 2002) suppresses the
neovascularization of tumoural tissues
and of ischaemic retinas.
The Role of Erythropoi-
etin (Epo)
Erythropoietin (Epo) is a glycoprotein
that is produced in the adult kidney
and the fetal liver (Jacobson et al.
1957; Zanjani et al. 1977). Epo binds
to a homodimeric Epo receptor
(EpoR), which stimulates erythropoie-
sis, and to a heterodimeric receptor,
which contains EpoR and the com-
mon b receptor (bC-R) and which
performs all of the other functions of
Epo (Sautina et al. 2010).
Epo might function in non-ery-
throid cells. EpoR is present in endo-
thelial cells, smooth muscle cells, B
cells, rodent placenta cells, embryonic
stem cells, megakaryocytes and neuro-
nal cells (Ishibashi et al. 1987; Sawyer
et al. 1989; Anagnostou et al. 1990,
1994; Kimata et al. 1991; Schmitt
et al. 1991; Heberlein et al. 1992; Car-
lini et al. 1993, 1995; Masuda et al.
1993; Gogusev et al. 1994; Digcaylio-
glu et al. 1995). Some neuronal cells
express EpoR on their surface, and
Epo binding to EpoR increases intra-
cellular Ca2+ and monoamine concen-
trations (Masuda et al. 1993). Konishi
et al. (1993) demonstrated that choline
acetyltransferase expression increases
after Epo stimulation in cultured
embryonic neurons, promoting the
in vivo survival of cholinergic neurons
in adult rats. Thus, Epo has been
hypothesized to act as a neurotrophic
factor.
The presence of Epo and EpoR in
the retina supports the hypothesis that
these molecules might play different
roles (Koury & Bondurant 1990). Sev-
eral authors have demonstrated the
protective effect of Epo against light-
induced retinal degeneration, ischae-
mia–reperfusion injury, neuronal cell
death and even against human stroke
(Konishi et al. 1993; Sakanaka et al.
1998; Siren et al. 2001; Ehrenreich
et al. 2002; Grimm et al. 2002; Junk
et al. 2002).
Yamaji et al. (1996) suggested that
Epo is a mitogenic factor for the
endothelial cells of brain capillaries,
showing that Epo performs an
endocrine function in kidney and tes-
tis cells and a paracrine function in
brain astrocytes during hypoxic condi-
tions.
Anagnostou et al. (1990) demon-
strated that recombinant human Epo
(rhEpo) elicits chemotactic and prolif-
erative effects in human umbilical vein
endothelial cells. Carlini et al. observed
that Epo increases endothelin-1 expres-
sion in bovine pulmonary artery endo-
thelial cells and stimulates angiogenesis
in rat thoracic aorta (Carlini et al.
1993, 1995).
Hypoxia stimulates Epo secretion,
which in turn increases erythrocyte
numbers and angiogenesis. Epo and
VEGF are both stimulated by HIF-1a
during hypoxia. Studies in cystic fibro-
sis patients showed that increased
VEGF is associated with increased
Epo during hypoxia (Watts & McCol-
ley 2011). Gess et al. (1996) showed
that the expression of Epo mRNA
increased 20-fold, whereas the VEGF
188, 164 and 120 mRNAs increased
two-, three- and sixfold, respectively,
in rat cultured hepatocytes exposed to
extreme hypoxia. Epo and VEGF
exhibit similar characteristics, as both
are induced by hypoxia (Krantz
1991). Similarly, Epo increases during
ischaemia, and its inhibition reduces
retinal oxygen-induced angiogenesis
(Watanabe et al. 2005).
Watanabe et al. observed high vitre-
al Epo in patients with diabetic reti-
nopathy compared to healthy
patients. The study showed that vitre-
al Epo was higher than vitreal VEGF
and than serum Epo levels, demon-
strating that increased Epo is unre-
lated to VEGF and that retinal tissues
are able to produce Epo. Therefore,
Epo inhibition during the growth
phase inhibited neovascularization in
a mouse model of proliferative reti-
nopathy (Watanabe et al. 2005).
Chen et al. (2008) studied the con-
tribution of Epo to every phase of
oxygen-induced retinopathy and
found that Epo deficiency contributes
to the development of the disease dur-
ing the first phase of retinopathy. The
administration of Epo prevents the
loss of vasculature and ischaemia at
this stage. These results suggest that
treating the patients at an early stage
of retinopathy might prevent the dam-
age following retinal neovasculariza-
tion. In contrast, treatment during the
late stage of neovascularization might
exacerbate the disease by promoting
endothelial cell proliferation (Chen
et al. 2008) (Table 1).
The mechanisms by which Epo
induces angiogenesis are not fully
known. There is evidence that it
increases NO production through
direct stimulation of endothelial nitric
oxide synthase (eNOS) and by stimu-
lating the proliferation, differentiation,
mobilization and the adhesion of
endothelial progenitor cells (Heeschen
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et al. 2003; Beleslin-Cokic et al. 2004;
Westenbrink et al. 2007). NO induc-
tion depends on bC-R and KDR stim-
ulation and the interaction between
bC-R and KDR receptors, and bC-R
blockade can decrease NO production
(Sautina et al. 2010; Su et al. 2011)
(Fig. 1).
Over the past 20 years, Epo treat-
ment has become an important part
of premature baby care. Its use has
increased to reduce the number of
blood transfusions required by these
small patients. Studies on the use of
Epo during the neonatal period have
increased in recent years (Shannon
et al. 1991; Gumy-Pause et al. 2005).
Some studies did not find an increase
of retinopathy associated with Epo
use, whereas others observed an
increase in ROP incidence with the
administration of rhEpo (Donato
et al. 2000; Romagnoli et al. 2000;
Maier et al. 2002; Turker et al. 2005;
Brown et al. 2006; Shah et al. 2010).
A meta-analysis conducted by Ohls-
son and Aher found an increase in
severe ROP (stage 3) in patients trea-
ted with rhEpo compared to control-
treated patients and an increase in all
stages when the treatments were
started within the first 8 days of life
(Aher & Ohlsson 2006; Ohlsson &
Aher 2006). Brown et al. (2006)
observed that the use of higher cumu-
lative doses of rhEpo was associated
with an increased risk of retinopathy
progression. Suk et al. (2008) assessed
the effects of the dosage and duration
of administration of Epo on the devel-
opment of ROP and reported that
babies who received more than 20
doses of rhEpo and who started this
treatment after 20 days of life exhib-
ited an increased risk of ROP com-
pared with those who received less
than 20 doses and started this drug
before the 20th day of life. A recent
retrospective analysis of 718 very low
birthweight babies showed that early
use of Epo did not lead to an
increased risk of severe ROP (only
stage 1). The authors found that
severe ROP was associated with lower
birthweight and gestational age and
required more aggressive therapy.
They speculated that the increase in
stage 3 ROP observed in other studies
might be due to the concomitant
actions of Epo and high doses of iron
(Figueras-Aloy et al. 2010). Excessive
levels of iron are toxic to tissues due
to the Fenton reaction; production of
hydroxyl radicals can cause oxidative
damage to lipids, proteins and DNA
(Sullivan 1988; Hesse et al. 1997; Loh
et al. 2009).
New Hypothesis
At present, new pathogenetic hypothe-
ses are associated with previous
knowledge. The studies on the role of
genetic components, nitric oxide,
adenosine, apelin and b-adrenergic
receptor (b-ARs) have opened new
gates to the treatment of ROP.
The Genetic Components
of ROP
Although ROP exhibits the same inci-
dence rates in Caucasian and Black
populations, the progression to severe
stages is more frequent in Caucasian
than in Black infants and in males
than in females (Saunders et al. 1997;
Good et al. 2005, 2012; Csak et al.
2006). The major susceptibility factor
for ROP progression in Caucasian is
the increased frequency of polymor-
phisms of b-adrenoreceptors (b-ARs)
in Black than in Caucasian infants
(Saunders et al. 1997; Good et al.
2005, 2012). Indeed, the ROP was
once considered as a result of
increased retinal pigmentation (Saun-
ders et al. 1997) appears to be attrib-
uted to a polymorphism of G protein–
coupled receptor kinase 5 (GRK5),
which desensitizes b-ARs (Liggett
et al. 2008, Good et al. 2012). The
GRK5 polymorphism blocks b-ARs
in Black patients, causing resistance to
noradrenergic stimuli and conferring
protection against heart failure, myo-
cardial ischaemia and also against
ROP (Good et al. 2012). The protec-
tive polymorphism suggests that phar-
macological blockage of b-ARs might
decrease ROP progression by reducing
the neovascularization induced by
b-stimuli (Good et al. 2012).
Therefore, the gene mutations and
single-nucleotide polymorphisms (SNP)
of ROP-related factors might play sig-
nificant roles in the development of
this multifactorial disease. Several
genetic mutations are associated with
the development of ROP. Studies by
Shastry et al. (1997) and by Hiraoka
et al. (2001) found that the mutation
of the Norrie disease protein gene
(NDP) increased the risk of severe
ROP. In contrast, Haider et al. (2000,
2001) failed to demonstrate an associ-
ation with the mutations of NDP
(R121W and L108P, A105T and
Val60Glu) with the progression of
ROP in Kuwaiti populations (Haider
et al. 2000, 2001). Furthermore, a
more frequent correlation between
ROP and a C597A polymorphism was
reported (Haider et al. 2002).
More recently, mutations in the
three genes (NDP, FZD4 and LRP5)
involved in the function of the wing-
less ⁄ integrated (Wnt) receptor signal-
ling pathway, which have been
associated with familial exudative vit-
reoretinopathy, were also correlated
with an increased risk of severe ROP
(Hiraoka et al. 2010; Shastry 2010).
ROP is also associated with SNPs of
the eNOS gene (T-786C and G894T)
(Yanamandra et al. 2010), complement
factor H (CFH) genes and of the
EPAS1 gene (Mohamed et al. 2009).
Genetic factors, along with prematurity
and early exposure to oxygen, appear
to play key roles in the development of
ROP. Future investigations of SNPs
may provide valuable insight into the
pathogenetic mechanisms underlying
the development of ROP.
The Role of Nitric
Oxide (NO)
Nitric oxide (NO) is a key signalling
molecule that mediates several basic
physiological processes, including neu-
rotransmission, vasodilatation and
host cell defence (Christopherson &
Bredt 1997; MacMicking et al. 1997;
Nathan 1997). NO is synthesized from
L-arginine by NOS. There are two
isoforms of NOS, constitutive (cNOS)
and inducible (iNOS) (Stuehr 1999).
The neuronal NOS (nNOS or NOS1)
and endothelial NOS (eNOS or
NOS3) are constitutive enzymes that
synthesize NO following an increase
in Ca2+ or after exposure to Ca2+ -
independent stimuli, such as shear
stress (Fleming et al. 1998). iNOS, or
NOS2, is Ca2+ -independent and con-
stitutively expressed only in select tis-
sues, such as the lung epithelium
(Dweik et al. 1998). It is usually syn-
thesized following the exposure to
proinflammatory stimuli (Kroncke
et al. 1995; Hierholzer et al. 1998).
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NOS isoforms have been identified
in the eyes of both animals and
humans (Goureau et al. 1993, 1994;
Yamamoto et al. 1993; Kobayashi
et al. 2000; Neufeld et al. 2000). NOS
isoforms are also present in the vascu-
lar endothelium and in pericytes (Cha-
kravarthy et al. 1995; Meyer et al.
1999). Martin et al. (2000) described
how pericytes control endothelial cell
growth by stimulating or inhibiting
cNOS or iNOS, respectively. nNOS is
expressed at low levels in the lamina
cribrosa and in the astrocytes of the
optic nerve head (Neufeld et al. 1997;
Shareef et al. 1999). eNOS is present
in the endothelium of the optic nerve
head and choroidal blood vessels but
is scarcely detectable in nonvascular
choroidal and scleral endothelial cells
(Neufeld et al. 1997; Poukens et al.
1998; Meyer et al. 1999; Shareef et al.
1999).
NO is a principal determinant of
choroidal and retinal blood flow (Se-
ligsohn & Bill 1993; Ostwald et al.
1997; Granstam et al. 1998; Granstam
& Granstam 1999; Schmetterer &
Polak 2001). Additionally, NO is
involved in the pathogenesis of retinal
and brain injury after a hypoxic is-
chaemic insult (Dawson et al. 1991;
Iadecola 1992; Samdani et al. 1997;
Adachi et al. 1998). Furthermore,
hypoxic injury increases retinal
mRNA and protein expression of
eNOS, leading to increased NO pro-
duction and consequently vasodilata-
tion and angiogenesis. Hashiguchi
et al. (2004) demonstrated that eNOS
expression elicits a neuroprotective
function during ischaemic conditions.
Kaur et al. (2006) postulated the exis-
tence of a balance between harmful
and protective factors after hypoxia.
An imbalance between these factors
might promote the adverse effects that
result in hypoxic retinal damage and
subsequent neovascularization.
Recently, He et al. (2007) showed
that iNOS modulates the activity of
HIF-1 via PI3K ⁄Akt signalling and
VEGF expression in the OIR mouse
model (Fig. 1). The authors observed
that a selective iNOS inhibitor
decreased the neoangiogenesis in ROP
animals treated with aminoguanidine
hemisulphate. This led them to
hypothesize a therapeutic role of
iNOS inhibitors for the treatment of
ROP (He et al. 2007).
Yuan and Ziche showed that NO
stimulates the proliferation and migra-
tion of endothelial cells (Yuan et al.
1993; Ziche et al. 1993, 1997). The
NO pathway might therefore be the
core component that is affecting
VEGF in this context. Cellular prolif-
eration occurs after VEGF stimula-
tion through the accumulation of NO
and cGMP (Morbidelli et al. 1996).
The inhibition of NO synthesis inhib-
its cell proliferation and the stimula-
tion of protein kinase mitogenic
activity. Similarly, the increase in cell
permeability induced by VEGF
appears to depend on the action of
NO (Wu et al. 1996).
Although it is constitutively
expressed, eNOS expression can also
be regulated by different stimuli
(Inoue et al. 1995; Liao et al. 1995;
Uematsu et al. 1995). Hood et al.
(1998) showed that there is a dose-
dependent increase in NO production
following VEGF stimuli. This increase
has a biphasic pattern, with peaks at
1 and 24 hr. Simultaneously, NO acti-
vates the transcription of the VEGF
gene, thereby playing a crucial role in
facilitating VEGF-induced angiogene-
sis (Jos´ko & Mazurek 2004).
Wu et al. (1996) observed that
VEGF induces vascular hyper-perme-
ability in a NO-dependent manner.
Lakshminarayanan et al. (2000) sug-
gested that the increased permeability
of the endothelial cells induced by NO
is attributed to the modulation of
tight junction proteins in response to
VEGF.
Data regarding the roles of eNOS
and NO in proliferative retinopathies
are apparently contradictory. On the
one hand, NO appears to inhibit
angiogenesis and to protect against
proliferative retinopathies. In fact, the
genetic polymorphisms and reduced
gene transcription of eNOS, which are
associated with lower serum levels of
NO metabolites (Li et al. 2004), are
significantly correlated with the devel-
opment of severe ROP in preterm
infants (Rusai et al. 2008; Yanaman-
dra et al. 2010). The reduced NO pro-
duction might aggravate the retinal
vascular obliteration observed during
the first phase of ROP, when the cap-
illaries of the developing retina of pre-
mature infants experience high
concentrations of oxygen, and thereby
promoting the neoangiogenesis
observed during the second phase of
ROP (Rusai et al. 2008) (Table 1).
On the other hand, NO appears to
increase neoangiogenic activity. Endo-
thelial NO synthase plays a predomi-
nant role in VEGF-induced
angiogenesis, as well as in vascular
permeability, and the lack of eNOS
contributes to the reduced angiogenic
response to VEGF observed in eNOS-
deficient mice (Fukumura et al. 2001).
The developing retina of eNOS-
deprived mice, induced either by gene
disruption or by pharmacological inhi-
bition (with the NOS inhibitor
N-nitro-L-arginine), is significantly
protected from hyperoxia-induced
damage and subsequent retinopathy
(Brooks et al. 2001; Ando et al. 2002)
by a mechanism that appears to be
independent of VEGF expression
(Brooks et al. 2001).
In the premature retina, impaired
circulation, which leads to ischaemia,
predisposes the retina to abnormal
preretinal neovascularization (Hardy
et al. 2000). The increased production
of NO and prostacyclin (PGI2)
improves ocular blood flow, resulting
in oxygen delivery to an immature ret-
ina that is devoid of antioxidant
defences; tissue oxygenation induces
ROS production, which significantly
contributes to the pathogenesis of
ROP (Toda & Nakanishi-Toda 2007).
NO production was proposed to
represent a compensatory mechanism
to induce vasodilation effects and to
reduce the vascular obliteration
observed in the early stages of OIR.
However, as OIR progresses to a later
stage, the excessive production of NO
might become deleterious, promoting
neovascularization. However, it is dif-
ficult to explain why a strong activa-
tion of NOS and consequent NO
production occur during the prolifera-
tive phase of ROP.
The Role of Adenosine
Adenosine is an endogenous purine
nucleotide that has fundamental bio-
logical functions, such as the transfer
of energy (conversion of ATP to
ADP), signal transduction (cAMP)
and inhibitory neurotransmission
(Collis & Hourani 1993; Johnson
et al. 1999; Wurm et al. 2008; Ibrahim
et al. 2011). The adenosine level
increases with increasing tissue activ-
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ity, stress or hypoxia. In fact, the
activity of adenosine is higher where
oxygen demand is highest, such as in
the retina. Adenosine is derived from
hydrolysis of cytoplasmic S-adenosyl-
homocysteine in the myocardium,
whereas it is produced from the
hydrolysis of AMP by the action of
the 5¢ nucleotidase (5¢N) in the retinal
Muller cells. Adenosine binds four dif-
ferent receptors (A1, A2A, A2B and
A3), which are all coupled to G pro-
teins (Blazynski 1987; Freissmuth
et al. 1991; Stefanovic et al. 1993; Ab-
bracchio et al. 1995; Palmer et al.
1995; Liang 1996; Zhao et al. 1997,
2000; Abebe & Mustafa 1998; Marala
& Mustafa 1998; Li & Wong 2000;
Montesinos et al. 2002; Lutty &
McLeod 2003).
Adenosine can act as a vasocon-
strictor or vasodilator, depending on
the tissue involved and the receptors
that are present (Tabrizchi & Bedi
2001). Vasodilation is induced by the
direct stimulation of NO production
(Olanrewaju & Mustafa 2000). In
addition, adenosine appears to elicit
anti-inflammatory activities, as it is
present in high amounts in inflamed
tissues (Cronstein et al. 1983, 1985,
1992; Ralevic & Burnstock 1998;
Awad et al. 2006; Liou et al. 2008).
Studies in chicken chorioallantoic
membranes have also demonstrated
that hypoxia stimulates angiogenesis
through adenosine production and
uptake (Dusseau & Hutchins 1988;
Grant et al. 1999; Taomoto et al.
2000; Grant et al. 2001; Lutty et al.
2000). Adenosine is a mitogenic, che-
motactic and proliferative factor (Teu-
scher & Weidlich 1985; Meininger
et al. 1988; Lutty et al. 1998). Fur-
thermore, adenosine directly stimu-
lates VEGF production during
hypoxia (Fischer et al. 1995; Takagi
et al. 1996a,b; Grant et al. 2001).
Adenosine and the A2A receptor
present on angioblasts and endothelial
cells are elevated during retinal devel-
opment. The hyperoxic phase of ROP
is characterized by a reduction in the
5¢N activity and adenosine levels. The
subsequent hypoxic vasoproliferative
phase is characterized by angiogenesis,
high activity of 5¢N and high levels of
adenosine (Fig. 1; Table 1).
Inhibition of adenosine or, prefera-
bly, of A2 receptors might represent a
therapeutic target to block the retinal
angiogenesis. The use of systemic A2
receptor antagonists might elicit
adverse effects not only on the heart
or on the central nervous system but
also on the retina because they block
normal vasculogenesis, resulting in
persistent avascular retina. Therefore,
the therapeutic blockade of A2 recep-
tors should be local and short term
(Lutty & McLeod 2003).
The Role of Apelin
Apelin is a peptide transcribed by a
gene on chromosome Xq25–26.1 in
humans (Tatemoto et al. 1998). When
it binds to the cognate apelin receptor
(APJ), it inhibits cAMP-induced fors-
kolin production, suggesting that the
receptor is coupled to the inhibitory
G protein (Gi). Activation of the APJ
receptor also mediates Ras-indepen-
dent activation of extracellular regu-
lated kinases (ERKs) by PKC
(Hosoya et al. 2000; Reaux et al.
2001; Masri et al. 2002; Zhou et al.
2003). The APJ ⁄apelin pathway is
active in several cells, organs and
peripheral tissues (lung, heart, liver,
kidney, adipose tissue, intestine, brain,
endothelium, mammary gland and
plasma) and regulates cardiovascular
activity, cell growth, apoptosis, metab-
olism, fluid homeostasis and immune
response. This pathway plays an
angiogenic role. It is likely that apelin
regulates vasculogenesis and angiogen-
esis (Devic et al. 1999; Saint-Geniez
et al. 2002; Kasai et al. 2004; Cox
et al. 2006; Sorli et al. 2007).
Kasai et al. (2004) showed that the
APJ ⁄apelin pathway is highly active
in RF ⁄ 6A retinal endothelial cells.
The administration of apelin promotes
migration, proliferation and capillary
formation. APJ genes are highly
expressed during embryonic vasculo-
genesis and postnatal retinal vessel
development (Devic et al. 1999; Saint-
Geniez et al. 2002). Similarly, this
pathway is active in many tumoural
tissues, which are areas of intense neo-
vascularization (Sorli et al. 2007). Cox
et al. (2006) showed that apelin is
required during normal development
of blood vessels in frog embryos. This
activity is VEGF-independent because
the suppression of VEGF with a
KDR inhibitor does not inhibit the
cell proliferation induced by apelin.
The molecular mechanisms that reg-
ulate the release of apelin remain
unknown, although recent data sug-
gest that HIF-1 promotes the expres-
sion of apelin in adipocytes and
cardiomyocytes (Kalin et al. 2007;
Eyries et al. 2008).
Kasai et al. (2008) showed delayed
development and a reduced angiogenic
response to VEGF in apelin knockout
mice, supporting the co-operative
activities between VEGF and apelin.
Apelin induces retinal neovasculariza-
tion during the hypoxic phase in OIR
mice. However, apelin stimulates
angiogenesis through APJ directly and
not through growth factors (Kasai
et al. 2010). The detailed mechanism
by which this occurs is still unknown,
but it appears that apelin ⁄APJ bind-
ing activates eNOS through PI3K ⁄Akt
signalling, which results in increased
NO production (Fig. 1) (Katugampola
et al. 2001; Tatemoto et al. 2001; Jia
et al. 2007; Kojima & Quertermous
2008). Therefore, apelin induces the
proliferation of endothelial cells inde-
pendently of VEGF (Kasai et al.
2010). Thus, it appears that hypoxia,
and specifically HIF-1a, stimulates the
expression of HRE-containing genes
to activate apelin production (Fig. 1)
(Eyries et al. 2008).
The vitreal apelin concentration
also increases in patients with diabetic
retinopathy, whereas it is not signifi-
cantly associated with increased
VEGF or plasma apelin concentra-
tions. Therefore, apelin is hypothe-
sized to be produced locally and
elicits autocrine functions in endothe-
lial cells (Tao et al. 2010).
Taken together, these data strongly
suggest that the apelin ⁄APJ pathway
plays a vital role in normal and path-
ological retinal angiogenesis (Table 1).
The Role of b-Adrener-
gic Receptors (b-ARs)
Adrenaline and noradrenaline (NA)
are catecholamines that are actively
involved in several age-related dis-
eases. The adrenergic receptors are
metabotropic G protein–coupled
receptors. Several cells express these
receptors on their surfaces, and their
binding to agonists induces a sympa-
thetic response. There are two classes
of adrenergic receptors (a-AR and
b-AR) and five major subtypes (a1-AR,
a2-AR, b1-AR, b2-AR and b3-AR)
(Hieble et al. 1995). Ageing is associ-
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ated with sympathetic denervation
(Burnstock 1990). In the retina, the
level of dopamine b-hydroxylase, the
enzyme that converts dopamine to
NA, decreases during ageing, and the
expression of b1-AR consequently
increases as a consequence of age-
related denervation (Smith et al.
2007). Sympathetic innervation plays
a fundamental role in regulating
ocular vascular architecture. Steinle
et al. (2002) showed that a superior
cervical ganglionectomy could increase
choroidal thickness and vascularity.
Moreover, the blockade of b-AR reca-
pitulated the results obtained with
denervation. Therefore, the activation
of b-AR is essential for the prevention
of an abnormal vasculature (Steinle &
Smith 2002).
Studies have demonstrated that
angiogenesis is controlled by the
adrenergic system through its regula-
tion of proangiogenic factors. b-ARs
are widely expressed in vascular endo-
thelial cells (Guimaraes & Moura
2001), and b2-ARs can regulate neo-
angiogenesis in response to chronic
ischaemia. In fact, in the endothelium
of the rat femoral artery, hind limb
ischaemia induces b2-AR overexpres-
sion in endothelial cells, promoting
VEGF production and function,
including cell proliferation and revas-
cularization. This observation suggests
a novel and physiologically relevant
role of such receptors in neoangiogen-
esis in response to ischaemia (Iaccari-
no et al. 2005). In several systems,
hypoxia causes catecholaminergic
overstimulation, which in turn alters
signalling pathways that are associ-
ated with b-ARs (Lindgren & Altim-
iras 2009).
Propranolol, a well-tolerated, non-
selective b-AR blocker, reduces the
growth of infantile capillary haeman-
giomas, the most common tumour
that affects infants (Leaute-Labreze
et al. 2008). Although there is no gen-
erally accepted mechanism for this
function, it has been hypothesized that
propranolol might act by reducing
VEGF levels (Sans et al. 2009; Storch
& Hoeger 2010). The possibility of a
relationship between the adrenergic
system and angiogenesis is supported
by the data from solid tumours and
tumoural cell lines, in which NA pro-
motes tumour progression by up-regu-
lating VEGF (Guo et al. 2009; Yang
et al. 2009). In addition, in human
umbilical vein endothelial cells, NA
stimulates VEGF production (Seya
et al. 2006). Finally, NA has been
found to stimulate angiogenesis by
up-regulating VEGF in neonatal rat
cardiac myocytes (Weil et al. 2003).
A role of b-ARs in the vascular
remodelling of the rat choroid has
been demonstrated (Steinle & Smith
2002), and b-AR expression in the ret-
ina has been established (Kubrusly
et al. 2007; Smith et al. 2007; Walker
& Steinle 2007). b-AR messengers and
proteins are expressed in the retina,
including b1- and b2-ARs in rats
(Smith et al. 2007) and b1-ARs in
birds (Kubrusly et al. 2007). b1- and
b2-ARs are expressed in rat Muller
cells, in which they influence cytokine
production in response to hyperglyca-
emia (Walker & Steinle 2007). In the
human retinal pigment epithelium,
b-ARs appear to regulate the produc-
tion of the antiangiogenic protein
pigment epithelium-derived factor
(Lashbrook & Steinle 2005). b1- and
b3-ARs, but not b2-ARs, are
expressed in human retinal and cho-
roidal endothelial cells. In these cells,
a role of b3-ARs in angiogenic pro-
cesses has been demonstrated (Fig. 1)
(Steinle et al. 2003, 2005). In addition,
pharmacological evidence shows that
b2- and b3-ARs are expressed in the
retinal blood vessels of the rat (Mori
et al. 2010).
Considering that b-AR stimulation
up-regulates VEGF and that the sec-
ond phase of ROP is promoted by
increased VEGF production, the over-
expression of VEGF during ROP has
been hypothesized to be induced by b-
AR stimulation, and furthermore, that
b-blockers might represent useful
agents in the treatment of ROP (Filip-
pi et al. 2010) (Fig. 2). This hypothe-
sis is supported by the observation
that infantile haemangiomas are asso-
ciated with ROP development, sug-
gesting a possible pathogenic
relationship between the two diseases
(Praveen et al. 2009).
However, data regarding the roles of
b-ARs in proliferative retinopathies
appear to be contradictory. In human
choroidal endothelial cells, the b-AR
agonist isoproterenol leads to increased
levels of growth factors implicated in
ocular diseases (Steinle et al. 2008), but
on the other hand, isoproterenol inhib-
its diabetic-like changes in the rat ret-
ina, suggesting that loss of b-AR
signalling might be a key factor in early
diabetic retinopathy (DR) (Jiang et al.
2010). Dal Monte et al. (2012)
observed, in an OIR model using
C57BL ⁄ 6J mice, that isoproterenol
reduced the levels of VEGF and the
formation of neovascular tufts as well
as promoted the down-regulation of
b2-ARs. Such antiangiogenic activity
was due to the reduced sensitivity of b-
receptors following an increase in b-
arrestin-1, b-arrestin-2 and G protein–
coupled receptor kinase 2 (GRK2)
(Dal Monte et al. 2012).
Propranolol does not affect the
VEGF retinal levels in rats with DR
(Zheng et al. 2007). In contrast, a
decrease in VEGF has been observed
in the retinas of neonatal OIR rats,
in which a reduction in intraocular
pressure induced by the b-AR antag-
onist timolol diminishes the severity
of OIR (Ricci et al. 1991, 1995,
2000). This discrepancy might be
explained by either the different drug
administration routes or different
dosages or the possibility that the
control of angiogenesis by b-ARs can
be regulated by distinct mechanisms
in OIR and DR.
In addition, there are conflicting and
opposing data on experimental models
of OIR. In C57BL ⁄ 6 OIR mice, treat-
ment with propranolol partially
restores the hypoxia-induced increase
in IGF-1 mRNA and VEGF mRNA
(Ristori et al. 2011). Furthermore,
VEGF protein is dose-dependently
reduced without affecting FLT-1,
KDR or IGF-1R mRNA levels (Chen
& Smith 2007; Ristori et al. 2011). Pro-
pranolol reduces VEGF overproduc-
tion in hypoxic retinas but does not
affect the VEGF level in normoxic reti-
nas, suggesting different patterns of
regulation of VEGF transcription dur-
ing normoxic and hypoxic conditions.
This possibility is supported by the
additional finding that b-AR blockade
does not influence the VEGF level in
the brain, lung or heart, where VEGF
expression is not regulated by hypoxia,
indicating that these organs most likely
do not experience hypoxia in the OIR
model. These data suggest that only
VEGF production during hypoxia-
ischaemia, which is most likely induced
by HIF-1a, might be affected by the
inhibition of b-ARs (Ristori et al.
2011). On the other hand, Chen et al.
(2012) recently observed that in an
OIR model performed in 129S6 mice,
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the administration of propranolol did
not reduce VEGF levels or the extent
of neovascularization. These apparent
contradictions might be explained by
the use of different strains of mice. In
fact, the severity of the OIR varies
according to the strain used, and occa-
sionally, in the case of the same strain
and vendor, on the origin of the strains
(Europe, Asia, America) (Stahl et al.
2010). In addition, the 129 strain is
significantly more susceptible to reti-
nal neovascularization induced by
hypoxia, exhibiting increased intrareti-
nal and intravitreal angiogenesis and
amplified VEGF mRNA expression
compared to the C57BL strain (Chan
et al. 2005). Ultimately, the difference
in gene expression of the different
strains, 129 and C57BL, changes the
role of the beta-receptors in hippocam-
pal synaptic plasticity (Schimanski
et al. 2007). Moreover, it is possible
that these differences are attributed to
a SNP harboured between the two
strains, consistent with what Good
et al. (2012) have reported to exist
between Caucasian and Black infants.
This would explain the predisposition
of 129 mice to develop more aggressive
neovascularization than that of
C57BL.
That propranolol (Ristori et al.
2011) and ICI 118,55, a selective b2-
AR blocker (Martini et al. 2011), sig-
nificantly inhibited hypoxia-induced
VEGF production provides the first
demonstration that b-ARs are coupled
to the modulation of VEGF in the
OIR model. Similarly, carvedilol,
another non-selective b-AR blocker,
reduces the expression of both HIF-1a
and VEGF in a rat model of cardiac
hypertrophy (Shyu et al. 2005). In
conclusion, these findings imply an
antiangiogenic and antipermeability
effect of b-AR blockade that is most
likely mediated through the down-reg-
ulation of VEGF and IGF-1 expres-
sion. The effect of propranolol on
VEGF expression is likely mediated
by HIF-1a. These results suggest a
theoretical activity of catecholamines
on the progression from the first to
the second stage of ROP.
Whereas the role of b2-ARs in the
pathogenesis of ROP might not be
probable, the involvement of b3-ARs
appears even less likely. An analysis
of b-AR expression in the retina
revealed that hypoxia up-regulates the
b3-ARs, which appeared to colocalize
with engorged retinal tufts in the inner
capillary network that reside within
the ganglion cell layer (Filippi et al.
2010). This observation is suggestive
of the possibility that b3-ARs might
mediate the onset of angiogenesis and
the antiangiogenic effects of propran-
olol on the retina of the OIR mice.
b3-ARs play a key role in regulating
the proliferation and migration of
human retinal endothelial cells (Steinle
et al. 2003). Additionally, in human
choroidal endothelial cells, b3-ARs
play a role in cellular invasion and
elongation (Steinle et al. 2005).
Intriguingly, in this animal model,
chronic ischaemia is hypothesized to
induce the overexpression of b3-ARs
in vascular endothelial cells, which in
turn could stimulate the activation
(crosstalk) of b2-ARs (Filippi et al.
2010). It is therefore likely that the
transition between the first and the
second phases of ROP is correlated
with the up-regulation of these b-ARs
(Fig. 2).
Further studies are needed to
understand the role of the b3-ARs in
the retina. In fact, the antagonists
used to evaluate their roles might act
as partial agonists (Vrydag & Michel
2007) or might not suppress their con-
stitutive activity (Perrone & Scilimati
2010).
A pilot randomized trial is actively
being conducted to verify whether
propranolol a well-tolerated, non-
selective b-AR blocker might reduce
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Fig. 2. Beta-adrenoreceptor stimulation and ROP. b-AR stimulation induces VEGF up-regula-
tion and overexpression. O2: oxygen; HIF-1: hypoxia-inducible factor 1; VEGF: vascular endo-
thelial growth factor; IGF-1: insulin-like growth factor-1; b2-AR: b2-adrenergic receptor; b3-
AR: b3-adrenergic receptor; mRNA: messenger ribonucleic acid; NA: noradrenaline; cAMP:
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tory G protein; ROP: retinopathy of Prematurity.
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the progression of ROP when admin-
istered to preterm newborns exhibiting
a precocious phase of ROP (Filippi
et al. 2010). Any favourable results of
this research might open new avenues
of research into the treatment or the
prevention of this and other prolifera-
tive retinopathies (Table 1).
Conclusions
Retinopathy of prematurity is a multi-
factorial disease that potentially
results in blindness. The increased sur-
vival of extremely premature infants is
associated with increased risk for the
development of ROP, prompting
research for early screening methods
and treatments that can reduce such
complications. The limitations of abla-
tive laser therapy and our growing
knowledge of the pathogenesis of
ROP have encouraged investigations
into new antivasculogenic therapies.
The recent development of HIF-1
inhibitors has triggered great interest
in their potential therapeutic applica-
tion. The inhibition of HIF-1 should
inhibit the production of proangiogen-
ic factors that cause neoangiogenesis
in numerous pathologies, including
ROP (Xia et al. 2012). In premature
babies, rhIGF-1 and rhEpo were
tested for their abilities to prevent the
loss of vasculature during the first
phase of ROP (Smith 2004; Chen
et al. 2008; Vanhaesebrouck et al.
2009), whereas anti-VEGF drugs have
been administered during the second
phase of ROP. However, few studies
have evaluated their efficacy and
safety (Darlow et al. 2011; Ha˚rd &
Hellstro¨m 2011). Although the effec-
tiveness of anti-VEGF treatment was
recently demonstrated (Mintz-Hittner
et al. 2011; Spandau et al. 2012), there
remain concerns and limitations about
its systemic safety. The anti-VEGF
drug persists in the blood long after
the initial intravitreal injection (Ma-
tsuyama et al. 2010; Lee et al. 2011;
Sato et al. 2012). Little is known
about its possible anti-VEGF effects
in the brain and the lungs. Based on
these uncertainties, it is necessary to
study new therapeutic strategies.
The notion of a gene or drug ther-
apy that inhibits PlGF is extremely
attractive but far from clinically appli-
cable in the near future (Luttun et al.
2002; Bae et al. 2005; Akrami et al.
2011). Similarly, more detailed studies
of adenosine receptors and their
antagonists will provide a solid basis
for targeted local therapy (Lutty &
McLeod 2003).
The genetic hypothesis that SNPs
of b-ARs actively contribute to the
pathogenesis of ROP supports the
notion that the prevention of this dis-
ease might be possible using b-block-
ers (Good et al. 2012).
Under these new pathogenic
hypotheses, the sympathetic nervous
system plays a central role by releas-
ing NA during hypoxic conditions,
triggering the b2 and b3-ARs, which
in turn should increase NO release.
Nitric oxide likely plays a predomi-
nant role in the progression from the
first to the second stage of ROP. In
fact, its increase might release the
proangiogenic factors that stimulate
retinal neoangiogenesis (Fig. 1).
Therefore, the local administration of
propranolol or of selective b2-AR
blockers, which would reduce the pos-
sible side-effects associated with their
systemic administration, might repre-
sent ideal treatment modalities for the
prevention of ROP from the earliest
stage of the disease. Local proprano-
lol, which elicits anti-VEGF activity
by blocking the excess circulating
VEGF without affecting the normal
vasculature of other organs and sys-
tems, might be the drug of choice to
understand and to prevent the patho-
genesis of ROP.
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